Aeterna Zentaris Inc. (AEZS)

NASDAQ: AEZS · IEX Real-Time Price · USD
1.950
0.00 (0.00%)
Apr 17, 2024, 12:30 PM EDT - Market open
0.00%
Market Cap 9.47M
Revenue (ttm) 4.50M
Net Income (ttm) -16.55M
Shares Out 4.86M
EPS (ttm) -3.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 491
Open 1.950
Previous Close 1.950
Day's Range 1.950 - 1.950
52-Week Range 1.360 - 3.380
Beta 2.07
Analysts Strong Buy
Price Target 15.00 (+669.23%)
Earnings Date May 7, 2024

About AEZS

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclin... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 1996
Employees 12
Stock Exchange NASDAQ
Ticker Symbol AEZS
Full Company Profile

Financial Performance

In 2023, AEZS's revenue was $4.50 million, a decrease of -20.25% compared to the previous year's $5.64 million. Losses were -$16.55 million, -27.17% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for AEZS stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target
$15.0
(669.23% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that...

20 days ago - GlobeNewsWire

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

TORONTO and EDMONTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biop...

7 weeks ago - GlobeNewsWire

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") today announced that it has issued a Letter to Shareholders and Management Proxy Circular ahead ...

2 months ago - GlobeNewsWire

AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aeterna Zentaris Inc. (NASDAQ: AEZS) and Ceapro Inc. is fair to Aeterna shareholders. H...

4 months ago - Business Wire

Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceut...

4 months ago - GlobeNewsWire

Aeterna Zentaris Reports Second Quarter 2023 Financial Results

TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing ...

9 months ago - GlobeNewsWire

Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

TORONTO, ONTARIO, July 13, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing ...

9 months ago - GlobeNewsWire

Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Thursday, July 13 th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...

10 months ago - GlobeNewsWire

Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...

10 months ago - GlobeNewsWire

Aeterna Zentaris Reports First Quarter 2023 Financial Results

– Ended the quarter with $ 46 . 6 million in cash, expected to fund operations into 2025

1 year ago - GlobeNewsWire

Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

TORONTO, ONTARIO, April 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...

1 year ago - GlobeNewsWire

Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025 – Executing strategy to streamline advancement of development programs, build upon growing b...

1 year ago - GlobeNewsWire

Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)

TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...

1 year ago - GlobeNewsWire

Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

TORONTO, ONTARIO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing ...

1 year ago - GlobeNewsWire

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Thursday , January 19 th at 3 :00 PM ET

1 year ago - GlobeNewsWire

Aeterna Zentaris Reports Third Quarter 2022 Financial Results

– Company ended the quarter with $ 53.8 million in cash

1 year ago - GlobeNewsWire

Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk

– Company plans to prioritize efforts to identify new strategic development and commercialization partner

1 year ago - GlobeNewsWire

Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

– Company ended the quarter with $58.2 million in cash

1 year ago - GlobeNewsWire

Aeterna Zentaris Announces Effective Date of Share Consolidation

TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing thera...

1 year ago - GlobeNewsWire

Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...

1 year ago - GlobeNewsWire

Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting

TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...

1 year ago - GlobeNewsWire

Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

- Vote to approve share consolidation adjourned to July 6, 2022

1 year ago - GlobeNewsWire

Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a...

2 years ago - GlobeNewsWire

Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's Disease

– Data presented at IMMUNOLOGY2022 ™ , the A nnual Event of the American Association of Immunologists

2 years ago - GlobeNewsWire